Loaʻa ka manaʻo maikaʻi mai ka European Medicines Agency's Committee for Medicinal Products no ka hoʻohana ʻana i ke kanaka i ka maʻi booster o Johnson & Johnson's COVID-19 kano.

ʻO Janssen, kahi hui ʻo Johnson & Johnson, ua hoʻolaha ke komite no nā huahana lāʻau lapaʻau no ka hoʻohana kanaka (CPMP)"I loko o ka European Medicines Agency i hāʻawi i kahi manaʻo maikaʻi e pili ana i ka hoʻohana ʻana i ka maʻi o Johnson & Johnson e kūʻē iā Covid-19 ma ke ʻano he booster dose.

Pili keia i na kanaka makua he 18 makahiki a oi, ma ka liʻiliʻi o ʻelua mahina ma hope o ka hoʻopaʻa ʻana mua me ka maʻi hoʻokahi o ka maʻi "Johnson & Johnson" kūʻē iā Covid-19, a ma ke ʻano he mea hoʻoikaika i hui pū ʻia me ka lāʻau lapaʻau mua me ʻelua mau kau o ka nā lāʻau lapaʻau RNA messenger (mRNA) i ʻae ʻia e kūʻē iā COVID-19 (i ʻike ʻia he heterologous boosting).^[1]

"ʻOliʻoli mākou i ka loaʻa ʻana o ka manaʻo maikaʻi mai ke komite e kākoʻo ana i ka hoʻohana ʻana i kā mākou kano Covid-19 ma ke ʻano he mea hoʻoikaika no nā poʻe kūpono ma ʻEulopa," wahi a Kauka Matai Mammen, Global Head of Research and Development for Janssen, a Johnson & ʻO Johnson lālā. Ke hōʻike nei ke kino o ka ʻikepili i ka hoʻoulu ʻana o ka maʻi maʻi ʻo Johnson & Johnson Covid-19 i nā pane ākea ākea a lōʻihi loa, inā hāʻawi ʻia ma ke ʻano hoʻokahi, a i ʻole ma ke ʻano he booster ma kahi o ʻelua mau mahina ma hope e hoʻoikaika i ka pale mai ka hōʻailona Covid-19.

Kākoʻo ʻia ka ʻōlelo a ka ʻaha kūkā e ka ʻikepili hou e pili ana i ka heterologous boosting me ka hoʻohana ʻana i ka maʻi "Johnson & Johnson" kūʻē iā Covid-19. ʻO ka ʻikepili mua mai kahi noiʻi e ka National Institute of Allergy and Infectious Diseases ma lalo o ke poʻo inoa "MixNMatch"ʻO kahi maʻi booster o ka maʻi "Johnson & Johnson" e kūʻē iā Covid-19 e hoʻonui i ka pane ʻana o ke kino, me ka nānā ʻole i ke ʻano o ke ʻano o ka maʻi mua.

Ua hoʻokumu ʻia ka manaʻo o ka Papa ma kahi pūʻolo ʻikepili kikoʻī i loaʻa nā hopena o ka haʻawina Phase 3 HUI-2 , ka mea i ʻike i ka loaʻa ʻana o kahi maʻi booster o ka maʻi "Johnson & Johnson Covid-19" ʻelua mahina ma hope o ka hāʻawi mua ʻana i ka 75% palekana mai (maʻalahi a koʻikoʻi) nā hōʻailona Covid-19 ma ka honua a me 94% pale aku (maʻalahi a koʻikoʻi) nā hōʻailona ma United States .Ua loaʻa pū i ka 100% ka pale ʻana i nā hihia koʻikoʻi Covid-19, ma kahi o 14 mau lā ma hope o ka hoʻomaʻamaʻa booster..  ʻO nā hoʻāʻo lāʻau lapaʻau, ke hāʻawi ʻia ma ke ʻano he mea hoʻoikaika a i ʻole ka hopena mua, ua hōʻike ʻia he hopena koʻikoʻi ma ka laulā, ʻoiai ʻaʻole i ʻike ʻia nā hōʻailona hou e pili ana i ka palekana o ke kano i ka wā o nā hoʻokolohua. pu 2 Hoʻohālikelike ʻia i nā haʻawina ʻelua-dose.

ʻO kahi haʻawina ʻelua i alakaʻi ʻia e Beth Israel Deaconess Medical Center i loaʻa kahi ʻāpana o nā mea komo VOC2008, kākoʻo ʻia e Janssen, nā pōmaikaʻi kūpono o ka hoʻoulu ʻana heterologous: ʻO ka hāʻawi ʻana i kahi maʻi booster o ka lāʻau lapaʻau Johnson & Johnson ʻeono mahina ma hope o ka loaʻa ʻana o ʻelua mau kau mua o ka lāʻau lapaʻau Pfizer/BioNTech i hoʻonui ʻia i ka pane ʻana o ka antibody a me ka T-cell.

No kēia poʻe i komo, hoʻomau ka piʻi ʻana o nā helu antibody no ka liʻiliʻi he ʻehā pule, no ka poʻe i loaʻa ka hoʻoikaika like me kahi kano. BNT162b2Ua emi iho ka helu o ka Antibody mai ka pule ʻelua a i ka pule ʻehā ma hope o ka nui o ka booster, e hopena i nā pae like o nā antibodies i nā hui ʻelua.